Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therapy. These could help manage prostate cancer. Researchers want to study how imaging can provide a profile of prostate cancer. They want to collect data to make diagnosis and treatments better.

Objectives: To gather data about the radiological and clinical course of prostate cancer. To study imaging-based biomarkers of prostate cancer.

Eligibility: Men ages 18 and older with diagnosed or suspected prostate cancer

Design: Participants will give permission for researchers to use their medical history and records. Their data will be reviewed, collected, and analyzed. These include results of their tests and scans. Sponsoring Institution: National Cancer Institute

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with an increased risk for prostate cancer (strong family history and/or germline mutation in DNA repair genes), or with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.

• Age greater than or equal to 18 years

• Ability of subject to understand and the willingness to sign a written informed consent document.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Yolanda L McKinney, R.N.
ymckinney@mail.nih.gov
(240) 760-6095
Backup
Ismail B Turkbey, M.D.
turkbeyi@mail.nih.gov
(240) 760-6112
Time Frame
Start Date: 2018-02-26
Estimated Completion Date: 2033-12-31
Participants
Target number of participants: 10000
Treatments
1/ Cohort 1
Subjects with an increased risk of prostate cancer or a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
Related Therapeutic Areas
Sponsors
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov